ReviewArchives of microbiology2025
From pathogenicity to therapy: Investigating the Therapeutic Potential of Bacillus anthracis Anthrax Toxin in Novel Cancer Therapies and Oncological Research.
Review in Archives of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer continues to be a significant global health concern, with treatment alternatives that encompass radiotherapy, chemotherapy, surgical procedures, and novel methods utilizing bacterial toxins such as anthrax toxin. This review summarizes the significance, laboratory preparation, and application of anthrax toxin for targeting cancer cells, encompassing both basic and advanced scientific research. Additionally, between 2000 and 2025, we compiled several studies analyzing the impacts of different engineered anthrax toxins on various cancer models through an extensive review of biomedical databases. Overall, research indicates that using bacterial toxins for cancer therapy is still an encouraging concept. However, further studies and innovative approaches are necessary to improve the effectiveness of clinical trials. Laboratory studies have demonstrated that anthrax toxin can efficiently eliminate different kinds of cancer cells. Various studies indicate that engineered anthrax lethal toxin has diverse effects, such as selectively targeting cancer cells and reducing damage to healthy cells while accurately identifying and enhancing the immune system In-vitro. Numerous studies indicated that combining anthrax toxin with chemotherapy or radiation therapy to enhance the cytotoxic effect of the toxin on cancer cells could boost treatment effectiveness. Furthermore, studies suggest that the application of anthrax toxin for human cancer treatment is expected to rise in frequency shortly, because of challenges associated with traditional cancer therapies. This comprehensive review indicated that anthrax toxin has been confirmed in laboratory tests to effectively eradicate various cancer cells and could serve as a significant overview of the importance of anthrax toxin in cancer treatment.
Indexed as
Identifiers
40742462What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.